EUCTR2010-021874-12-BE进行中（未招募）不适用
A Phase 2, Randomized, Observer–blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine against S. Typhi in Adult Subjects 18 to 40 Years of Age.
ovartis Vaccines Institute for Global Health (NVGH)0 个研究点目标入组 88 人开始时间: 2010年8月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males and females of age =18 to =40 years.
- •2.Individuals who, after the nature of the study have been explained to them, have given written consent according to local regulatory requirements.
- •3.Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
- •4.Individuals with negative screening tests for drug addition as follows: opiate, cocaine, amphetamine/metamphetamine and cannabinoides.
- •5.If women, use of birth control one month before study start, a negative pregnancy test and willingness to use birth control measures for the entire study duration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- •2.Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
- •3.Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.
- •4.Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- •5.Individuals with known or suspected HIV infection or HIV related disease, with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days, or were in chemotherapy treatment within the past 6 months.
- •6.Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •7.Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
- •8.Individuals who have any malignancy or lymphoproliferative disorder.
- •9.Individuals with history of allergy to vaccine components.
- •10.Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
- •11.Individuals who have previously received any vaccines against typhoid fever (either oral live attenuated or injectable vaccines)
- •12.Individuals who received any other vaccines within 4 weeks prior to enrolment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccine
- •13.Individuals who have received blood, blood products and/or plasma derivatives including parenteral immunoglobulin preparations in the past 12 weeks.
- •14.Individuals who are part of study personnel or close family members to the personnel conducting this study.
- •15.Individuals with body temperature > 38.0 degrees Celsius within 3 days of intended study immunization.
- •16.BMI > 35 kg/m2.
- •17.Individuals with history of substance or alcohol abuse within the past 2 years.
- •18.Women who are pregnant or breast-feeding or of childbearing age who have not used any birth control measure one month prior to study start or do not plan to use acceptable birth control measures, for the duration of the study.
- •19.Females with history of stillbirth, neonatal loss, or previous infant with anomaly.
- •20.Individuals who have a previously ascertained or suspected disease caused by S. Typhi.
- •21.Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. Typhi.
- •22.Any condition which, in the opinion of the investigator may interfere with the evaluation of the study objectives.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersTo assess the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersMedDRA version: 16.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000862-13-ITovartis Vaccines and Diagnostics S.r.l.
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Subjects aged 6 months to 17 yearsMedDRA version: 9.1Level: LLTClassification code 10064097Term: Avian influenzaavian influenzaEUCTR2007-002480-27-FIovartis Vaccines and Diagnostics GmbH & Co. KG
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD-like Surface Antigen Adjuvanted with MF59C.1 Influenza Vaccines Containing 7.5 mg or 15 mg of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 mg of A/H5N1 Influenza Antigen, in Adults - NDActive influenza profilaxis pandemic strainMedDRA version: 8.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2006-004063-66-ITCHIRO
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two FLUAD-like Surface Antigen Adjuvanted with MF59C.1 Influenza Vaccines Containing 7.5 mcg or 15 mcg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects - NDActive influenza immunization pandemic strainsMedDRA version: 6.1Level: PTClassification code 10022000EUCTR2005-005871-14-ITCHIRO520
进行中（未招募）
不适用
A study to evaluate the safety and immunogenicity of a candidate Ebola Vaccine in children.EUCTR2014-004714-28-Outside-EU/EEAGlaxoSmithKline Biologicals600